Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

Biotechnology

Outlook Therapeutics

The Cranbury office focuses on overseeing technical operations and strategic initiatives within the organization.

Cranbury

Outlook Therapeutics' headquarters in Woodbridge Township, NJ, United States

Bob Jahr

Alison Oliver

Surendra Sharma

Jennifer Kissner

Dan Courtney

Terry Dagnon

Gerd Auffarth

Andong Huang

Randy Thurman

Faisal G. Sukhtian

Kurt J. Hilzinger

Julian Gangolli

Yezan Haddadin

The Directors team at Outlook Therapeutics encompasses a range of specialized leaders responsible for overseeing critical functions such as human resources, patient access and marketing, bioassay development, clinical affairs, physician relations, and financial planning and analysis. This team ensures strategic alignment and operational efficiency across various departments to support the clinical development and potential FDA approval of ONS-5010 / LYTENAVA™ (bevacizumab-vikg).

Directors

The Operations Team at Outlook Therapeutics is responsible for ensuring the seamless production, compliance, and delivery of ONS-5010 / LYTENAVA™ (bevacizumab-vikg). This includes overseeing manufacturing processes, supply chain management, quality assurance, and commercial operations to support the successful development and market introduction of the ophthalmic formulation for retinal diseases.

Operations Team

The Vice Presidents team at Outlook Therapeutics is responsible for high-level strategic oversight and decision-making across critical domains. This includes identifying and securing licensing opportunities and managing mergers and acquisitions (Senior Vice President, Licensing and Mergers & Acquisitions), overseeing clinical trials and ensuring regulatory compliance (Senior Vice President, Clinical & Regulatory Affairs), and guiding medical strategies and stakeholder engagement relating to ONS-5010 / LYTENAVA™ (Senior Vice President, Medical Affairs).

Vice Presidents

This department provides strategic oversight and governance for the organization.

Board Leadership

This department focuses on identifying growth opportunities, establishing partnerships, and driving sales strategies.

Business Development

This department oversees clinical trials, ensuring the safety and efficacy of products through strong pharmacovigilance and regulatory compliance.

Outlook Therapeutics

Org chart

Board & advisors

Teams

Directors

Operations Team

Vice Presidents

Board Leadership

Business Development

Clinical Operations

Offices

Outlook Therapeutics

Org chart

Board & advisors

Teams

Directors

Operations Team

Vice Presidents

Board Leadership

Business Development

Clinical Operations

Offices

Related companies